A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
The purpose of this study is to evaluate the safety and antiviral activity of
 ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267
 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin
 (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without
 cirrhosis.
A randomized, open-label, multicenter study to evaluate the safety and antiviral activity of
 the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with and without
 ribavirin (RBV) in treatment-experienced, noncirrhotic participants with chronic hepatitis C
 virus genotype 1b (HCV GT1b) infection.
Inclusion Criteria:

 -  Females must be practicing specific forms of birth control on study treatment, or be
 post-menopausal for more than 2 years or surgically sterile

 -  Chronic hepatitis C, genotype 1b-infection (HCV RNA level greater than or equal to
 10,000 IU/mL at screening)

 -  Subject's hepatitis C virus genotype is subgenotype 1b at Screening without co
 infection with any other genotype/subgenotype.

 Exclusion Criteria:

 -  Significant liver disease with any cause other than HCV as the primary cause

 -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

 -  Positive screen for drugs or alcohol

 -  Use of contraindicated medications within 2 weeks of dosing